Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05601414 · ClinicalTrials.gov registry record · NA
Blood Pressure Monitoring in Hypertensive Populations: Device Testing, Feasibility, Acceptability
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT05601414: Completed NA study, sponsored by Yale University.
NCT05601414 is a NA study that has completed, run by Yale University. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05601414, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
The goal of this study is to test a novel cuffless blood pressure (BP) monitoring device (BIO-Z) within adults with hypertension (high blood pressure) for clinical use. The main questions it aims to answer are: * To validate a novel cuffless blood pressure (BP) monitoring device (BIO-Z) within adults with hypertension (high blood pressure) * To assess BP monitoring accuracy, against reference BP measurements captured by a Finapres Nova® continuous BP monitoring device in correspondence with blood pressure monitoring devices standards. Researchers will test the device against the Finapres Nova® blood pressure monitoring device.
Primary Outcome
MAD value between the BIO-Z BP readings and the FDA- approved Finapres Nova® readings collected during the study visit will be calculated.
Interventions
- DEVICE BIO-Z
- DEVICE Finapres Nova
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2023-09-01 |
| Phase | NA |
What the finished NCT05601414 record still lists
NCT05601414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which BIO-Z is the first listed.
NCT05601414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05601414 about?
NCT05601414 is a clinical study titled "Blood Pressure Monitoring in Hypertensive Populations: Device Testing, Feasibility, Acceptability". The goal of this study is to test a novel cuffless blood pressure (BP) monitoring device (BIO-Z) within adults with hypertension (high blood pressure) for clinical use. The main questions it aims to answer are: * To validate a novel cuffless blood pressure (BP) monitoring device (BIO-Z) within adu...
What is the current status of trial NCT05601414?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2023-01-11. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05601414?
The interventions under investigation include: BIO-Z (DEVICE), Finapres Nova (DEVICE).
Who is sponsoring clinical trial NCT05601414?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05601414's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI